These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15169979)

  • 1. The miracle of Iressa.
    Chabner BA
    Oncologist; 2004; 9(3):245-6. PubMed ID: 15169979
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
    Price N; Belani C
    Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
    [No Abstract]   [Full Text] [Related]  

  • 3. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
    Madelaine J; Cadranel J; Zalcman G
    Rev Mal Respir; 2004 Nov; 21(5 Pt 1):881-5. PubMed ID: 15622331
    [No Abstract]   [Full Text] [Related]  

  • 5. EGFR mutation in gefitinib-responsive small-cell lung cancer.
    Okamoto I; Araki J; Suto R; Shimada M; Nakagawa K; Fukuoka M
    Ann Oncol; 2006 Jun; 17(6):1028-9. PubMed ID: 16357019
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
    Chic N; Mayo-de-Las-Casas C; Reguart N
    J Thorac Oncol; 2017 Jun; 12(6):e78-e80. PubMed ID: 28532569
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 May; 6(6):338-9. PubMed ID: 15943892
    [No Abstract]   [Full Text] [Related]  

  • 8. [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
    Kakiuchi S; Yano S; Sone S
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1831-8. PubMed ID: 16223143
    [No Abstract]   [Full Text] [Related]  

  • 9. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated data from the Iressa survival in lung cancer trial.
    Tyagi P
    Clin Lung Cancer; 2005 May; 6(6):340-2. PubMed ID: 15943893
    [No Abstract]   [Full Text] [Related]  

  • 11. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
    Kim YH; Mio T; Mishima M
    Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of clinical response of non-small cell cancer to gefitinib.
    Ardizzoni A; Tiseo M
    JAMA; 2004 Apr; 291(13):1563; author reply 1563-4. PubMed ID: 15069041
    [No Abstract]   [Full Text] [Related]  

  • 13. The 'Iressa' Clinical Experience Meeting. June 2003, Madrid, Spain. Proceedings and abstracts.
    Gatzemeier U
    Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S1-35. PubMed ID: 14661045
    [No Abstract]   [Full Text] [Related]  

  • 14. Hair growth after gefitinib treatment.
    Lee LW; Burt PA
    Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):492-3. PubMed ID: 16149296
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

  • 16. Commentary on ZD1839 (Iressa) in non small cell lung cancer.
    Ranson M; Thatcher N
    Lung Cancer; 2003 Apr; 40(1):77-8. PubMed ID: 12660010
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular targeted therapies and cytotoxics: Friends or foes?].
    Vignot S; Zalcman G
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
    [No Abstract]   [Full Text] [Related]  

  • 18. [Iressa (gefitinib)].
    Kudoh S; Yoshimura A; Gemma A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1079-84. PubMed ID: 12938261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 20. Is FISH floating or still swimming in the lung cancer ocean?
    Cappuzzo F; Camidge DR; Varella-Garcia M
    Ann Oncol; 2011 Mar; 22(3):493-499. PubMed ID: 21292645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.